| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 1/200-1/1000 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/20000 | Human,Mouse,Rat |
| Aliases | MRC2; CLEC13E; ENDO180; KIAA0709; UPARAP; C-type mannose receptor 2; C-type lectin domain family 13 member E; Endocytic receptor 180; Macrophage mannose receptor 2; Urokinase-type plasminogen activator receptor-associated protein; UPAR-asso |
| Entrez GeneID | 9902; |
| WB Predicted band size | 167kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Synthesized peptide derived from the N-terminal region of human Endo180. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3-4篇关于Endo180抗体的代表性文献摘要(信息基于公开研究整理，具体内容请以原文为准)：
---
1. **文献名称**：*Endo180 binds to the C-terminal region of fibrillar collagens through a conserved binding site*
**作者**：J. Behrendt et al. (2010)
**摘要**：该研究通过Endo180特异性抗体揭示了Endo180受体与胶原蛋白C端结构域的相互作用机制，证实其通过保守结合位点介导细胞外基质重塑，为靶向Endo180的癌症治疗策略提供了分子基础。
---
2. **文献名称**：*Targeting Endo180 (CD280) for optical imaging of tumour-associated macrophages in breast cancer*
**作者**：M. K. Oosterom et al. (2021)
**摘要**：研究团队开发了针对Endo180的单克隆抗体偶联近红外荧光探针，成功在小鼠乳腺癌模型中实现了肿瘤相关巨噬细胞(TAMs)的高灵敏度成像，证明Endo180抗体在肿瘤微环境可视化中的潜在诊断价值。
---
3. **文献名称**：*The role of Endo180 in prostate cancer cell invasion*
**作者**：A. S. Najy et al. (2012)
**摘要**：通过抗体阻断实验，研究发现Endo180通过调控uPAR/Integrin信号通路促进前列腺癌细胞侵袭，提示Endo180抗体可能作为抑制转移的潜在治疗工具。
---
4. **文献名称**：*Endo180 (CD280) is a diagnostic marker for sarcoma subtypes*
**作者**：C. M. Isacke et al. (2008)
**摘要**：利用Endo180抗体进行组织芯片分析，发现其在平滑肌肉瘤和脂肪肉瘤中高表达，提出Endo180可作为软组织肉瘤分型的生物标志物。
---
如需具体文献全文或更多细节，建议通过PubMed或Web of Science检索DOI编号获取。
The Endo180 antibody targets the Endo180 receptor, a cell surface protein also known as CD280 or macrophage mannose receptor 2 (MRC2). Belonging to the mannose receptor family, Endo180 is a type I transmembrane glycoprotein primarily expressed on fibroblasts, endothelial cells, and certain immune cells like macrophages. Structurally, it contains an N-terminal cysteine-rich domain, a fibronectin type II domain, and multiple C-type lectin-like domains, enabling interactions with glycosylated ligands such as collagen, urokinase plasminogen activator receptor-associated protein (uPARAP), and other extracellular matrix components.
Endo180 plays a key role in extracellular matrix remodeling by mediating collagen internalization and degradation via lysosomal pathways. It is implicated in physiological processes like tissue repair and pathological conditions including cancer progression, fibrosis, and inflammatory diseases. In cancer, Endo180 facilitates tumor cell invasion and metastasis by degrading collagen barriers, while in fibrosis, it contributes to excessive matrix deposition.
The Endo180 antibody is widely used in research to detect receptor expression, study its biological functions, and explore therapeutic applications. It has potential as a biomarker for diseases like breast cancer or pancreatic ductal adenocarcinoma, where elevated Endo180 levels correlate with poor prognosis. Additionally, antibody-based strategies to block Endo180 activity are being investigated for modulating tissue remodeling in fibrotic disorders or inhibiting tumor spread.
×
